Taken together, these results suggest that pharmacological inhibition of PRMT1 effectively eradicates LSCs, whereas does not damage normal hematopoiesis in CML mice. Here, PRMT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.